ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
Conditions: Endometrial Cancer; Recurrent Endometrial Cancer; TP53 Interventions: Drug: Abemaciclib; Drug: Letrozole; Drug: Pembrolizumab Sponsors: Dana-Farber Cancer Institute; Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
Conditions: Metastatic Cancer Interventions: Radiation: Stereotactic Radiotherapy Sponsors: Elsan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: Cadonilimab+Lenvatinib Sponsors: Shanghai Zhongshan Hospital; Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)
Conditions: Locally Advanced Lung Non-Small Cell Carcinoma Sponsors: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Politecnico di Milano Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Econd-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: Cadonilimab+Lenvatinib Sponsors: Hui-Chuan Sun; Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Conditions: Advanced Hepatocellular Carcinoma Interventions: Drug: camrelizumab Sponsors: Fujian Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: HAIC+STRIDE+Len Sponsors: Sulai Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Conditions: ALK-positive Non-small Cell Lung Cancer; Real World Study Interventions: Drug: Lorlatinib Sponsors: Sichuan Cancer Hospital and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Aromatase inhibitors or tamoxifen Sponsors: Medical College of Wisconsin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
Conditions: NSCLC Interventions: Drug: BPI-1178; Drug: Osimertinib Sponsors: National Cancer Center, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions: Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations Interventions: Drug: Alintegimod; Drug: Ipilimumab; Drug: Nivolumab Sponsors: 7 Hills Pharma, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours
Conditions: Advanced Cancer; Advanced Solid Tumor; Lymphoma, Hodgkin; Central Nervous System Tumor; Sarcoma; Germ Cell Tumor; Pediatric Cancer Interventions: Dietary Supplement: Ocoxin Oral solution Sponsors: Catalysis SL Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
PSMA Therapy and Immunotherapy in Kidney Cancer
Conditions: Metastatic Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: 177Lu-PNT2002; Drug: (F-18)-DCFPyL Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Merck Sharp& Dohme LLC; Lantheus Medical Imaging Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Probability of OncotypeDx to Reallocate as Low or High Risk of Recurrence Breast Cancer Patients With Uncertain Biology
Conditions: Breast Cancer Sponsors: Fondazione Sandro Pitigliani; Genomic Health ®, Inc.; Istituto Toscano Tumori Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
Conditions: Upper Gastrointestinal Cancer Interventions: Drug: Nivolumab Sponsors: Bristol-Myers Squibb Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
